• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=27594985; Cosmic-CLP=1503365; DepMap=ACH-001654).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (Cosmic-CLP=1503365; DepMap=ACH-001654).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln100Ter (c.298C>T); ClinVar=VCV000634707; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP=1503365; DepMap=ACH-001654).
  

PubMed=8334620; DOI=10.1002/1097-0142(19930801)72:3<649::aid-cncr2820720305>3.0.CO;2-L
Altorki N.K., Schwartz G.K., Blundell M.L., Davis B.M., Kelsen D.P., Albino A.P.
Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.
Cancer 72:649-657(1993)

PubMed=7665247; DOI=10.1002/ijc.2910640109
Nabeya Y., Loganzo F. Jr., Maslak P., Lai L., de Oliveira A.R., Schwartz G.K., Blundell M.L., Altorki N.K., Kelsen D.P., Albino A.P.
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
Int. J. Cancer 64:37-46(1995)

PubMed=11520067; DOI=10.1006/bbrc.2001.5400
Kan T., Shimada Y., Sato F., Maeda M., Kawabe A., Kaganoi J.-i., Itami A., Yamasaki S., Imamura M.
Gene expression profiling in human esophageal cancers using cDNA microarray.
Biochem. Biophys. Res. Commun. 286:792-801(2001)

PubMed=20075370; DOI=10.1093/jnci/djp499; PMCID=PMC2902814
Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P., Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K., Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H., Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J. Natl. Cancer Inst. 102:271-274(2010)

PubMed=20139130; DOI=10.1093/carcin/bgq036
Duggan S.P., Behan F.M., Kirca M., Smith S.M., Reynolds J.V., Long A., Kelleher D.P.
An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-kappaB activation and cytokine levels.
Carcinogenesis 31:936-945(2010)

PubMed=23795680; DOI=10.1111/dote.12095
Boonstra J.J., Tilanus H.W., Dinjens W.N.M.
Translational research on esophageal adenocarcinoma: from cell line to clinic.
Dis. Esophagus 28:90-96(2015)

PubMed=26317542; DOI=10.18632/oncotarget.4540; PMCID=PMC4694873
Chen Q.-R., Song S.-M., Wei S.-Z., Liu B., Honjo S., Scott A.W., Jin J.-K., Ma L., Zhu H.-T., Skinner H.D., Johnson R.L., Ajani J.A.
ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.
Oncotarget 6:25883-25896(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27594985; DOI=10.12688/f1000research.7033.1; PMCID=PMC4991527
Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J., Lynch A.G., Edwards P.A.W., Fitzgerald R.C.
Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.
F1000Research 5:1336.1-1336.12(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)